LogicBio Therapeutics (LOGC) Short Interest Ratio & Short Volume

Short interest is the volume of LogicBio Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 274,400 shares of LOGC short. 1.27% of LogicBio Therapeutics' shares are currently sold short. Learn More on LogicBio Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.27% of LogicBio Therapeutics' floating shares are currently sold short.

LogicBio Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 274,400 shares, an increase of 104.9% from the previous total of 133,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

LogicBio Therapeutics currently has issued a total of 32,963,000 shares. Some of LogicBio Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. LogicBio Therapeutics currently has a public float of 21,560,000 shares.

1.27% of LogicBio Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to LogicBio Therapeutics: Instil Bio, Inc. (0.23%), Elutia Inc. (0.19%), Genenta Science S.p.A. (0.02%), Turnstone Biologics Corp. (4.76%), Precision BioSciences, Inc. (9.69%), Ikena Oncology, Inc. (5.48%), Gritstone bio, Inc. (13.16%), Entera Bio Ltd. (0.31%), Aligos Therapeutics, Inc. (0.87%), Passage Bio, Inc. (4.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.81 billion), Charter Communications, Inc. ($3.04 billion), T. Rowe Price Group, Inc. ($1.98 billion), PG&E Co. ($1.92 billion), Lucid Group, Inc. ($1.90 billion), Coinbase Global, Inc. ($1.75 billion), Roblox Co. ($1.58 billion), Rivian Automotive, Inc. ($1.54 billion), Diamondback Energy, Inc. ($1.53 billion), and Old Dominion Freight Line, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling LOGC is an investing strategy that aims to generate trading profit from LogicBio Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for LogicBio Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LOGC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LOGC, twice per month. The most recent reporting period available is October, 31 2022.